 "Lupin launches anti-fungal drug voriconazole in US")
Lupin Limited has launched its voriconazole tablet (50 mg & 200 mg) and voriconazole oral suspension (40 mg/mL) having received an approval for these products from the US Food and Drug Administration (FDA) earlier. Voriconazole tablet and oral suspension are generic versions of Vfend tablet and Vfend oral suspension – manufactured by PF Prism CV.
Voriconazole is indicated for use in patients 12 years of age and older in the treatment of the fungal infections.
According to IMS MAT September 2016, Vfend tablets (50 mg & 200 mg) and oral suspension recorded US sales of $ 81 million and $ 15.2 million, respectively.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%